Open AccessLong-term carbimazole pretreatment reduces the efficacy of radioiodine therapy
Author(s) -
C Shivaprasad,
KM Prasanna Kumar
Publication year - 2015
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/2230-8210.146865
Subject(s) - carbimazole , medicine , propylthiouracil , methimazole , radioiodine therapy , antithyroid drugs , graves' disease , retrospective cohort study , antithyroid agent , gastroenterology , urology , endocrinology , nuclear medicine , disease , thyroid , thyroid cancer
Data from several studies suggest that pretreatment with antithyroid drugs (ATD) before (131)I increases the risk of treatment failure. This effect has been demonstrated more consistently with propylthiouracil than with carbimazole (CMZ) or methimazole (MMI). Men with Graves' disease (GD) have a lower rate of remission with (131)I compared to women and the impact of long-term ATD pretreatment on the success of (131)I is unknown. The objective of our study was to compare the efficacy of fixed doses of radioiodine between patients with and without long-term CMZ pretreatment.